Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
View Patent ↗The present invention relates, in general, to a screening method for identifying novel viral proteins with interferon antagonizing function using a transfection-based assay, and the use of such proteins in isolating various types of attenuated viruses for the development of vaccine and pharmaceutical formulations. The invention also relates to the use of viral interferon antagonists in screening assays to identify potential anti-viral agents. The invention further relates to protocols utilizing interferon antagonists, e.g., NS1, to enhance gene therapy or DNA vaccination based on their ability to increase gene expression.
1. A screening method for identifying a viral protein with an interferon-antagonizing function, comprising:
(a) infecting a cell with a chimeric virus, wherein the chimeric virus is constructed by engineering a parent RNA virus with impaired interferon antagonist activity to encode a heterologous viral protein; and
(b) determining the replication of the chimeric virus, wherein the heterologous viral protein is identified as having an interferon antagonizing function if the replication of the chimeric virus is increased relative to the replication of the parent of the chimeric virus which has impaired interferon antagonist activity and does not encode the heterologous viral protein.
2. A screening method for identifying a viral protein with an interferon-antagonizing function, comprising:
(a) contacting a viral protein with a cell infected with an RNA virus with impaired interferon antagonist activity; and
(b) determining the replication of the virus, wherein the viral protein is identified as having an interferon antagonizing function if the replication of the virus in the presence of the viral protein is increased relative to the replication of the virus in the absence of the viral protein.
3. A screening method for identifying a viral protein with an interferon-antagonizing function, comprising:
(a) infecting a cell that expresses a viral protein with an RNA virus with impaired interferon antagonist activity; and
(b) determining the level of expression of an interferon-responsive gene or the level of interferon-induced activation of a cellular protein, wherein the viral protein is identified as having an interferon antagonizing function if the level of expression of the interferon-responsive gene or the level of interferon-induced activation of a cellular protein in the presence of the viral protein is decreased relative to the level of expression of the interferon-responsive gene or the level of interferon-induced activation of a cellular protein in the absence of the viral protein.
4. A screening method for identifying a potential antiviral agent, comprising:
(a) contacting a test agent with a cell infected with a chimeric virus, wherein the chimeric virus is constructed by engineering a virus with impaired interferon antagonist activity to encode a heterologous viral interferon antagonist; and
(b) determining the replication of the chimeric virus, wherein the test agent is identified as a potential antiviral agent if the replication of the chimeric virus in the presence of the test agent is decreased relative to the replication of the chimeric virus in the absence of the test agent.
5. A screening method for identifying a potential antiviral agent, comprising:
(a) contacting a test agent with a cell that expresses a viral interferon antagonist, following stimulation of a cellular interferon response; and
(b) determining the level of expression of an interferon-responsive gene or the level of interferon-induced activation of a cellular protein, wherein the test agent is identified as a potential antiviral agent if the level of expression of the interferon-responsive gene or the level of interferon-induced activation of a cellular protein in the presence of the test agent is increased relative to the level of expression of the interferon-responsive gene or the level of interferon-induced activation of a cellular protein in the absence of the test agent.
6. The method of claim 1 , wherein the RNA virus is an influenza virus with a mutation in the NS1 gene.
7. The method of claim 4 , wherein the chimeric virus is an influenza virus with a mutation in the NS1 gene.
8. The method of claim 2 , wherein the RNA virus is an influenza virus with a mutation in the NS1 gene.
9. The method of claim 3 , wherein the RNA virus is an influenza virus with a mutation in the NS1 gene.
10. The method of claim 4 , wherein the viral interferon antagonist is influenza virus NS1 protein.
11. The method of claim 4 , wherein the viral interferon antagonist is vaccinia virus E3L protein.
12. The method of claim 4 , wherein the viral interferon antagonist is Ebola virus VP35 protein.
13. The method of claim 5 , wherein the viral interferon antagonist is influenza virus NS1 protein.
14. The method of claim 5 , wherein the viral interferon antagonist is vaccinia virus E3L protein.
15. The method of claim 5 , wherein the viral interferon antagonist is Ebola virus VP35 protein.
16. The method of claim 3 , wherein the interferon responsive gene is a reporter gene operatively linked to an interferon responsive promoter element.
17. The method of claim 5 , wherein the interferon responsive gene is a reporter gene operatively linked to an interferon responsive promoter element.
18. The method of claim 3 , wherein the interferon-induced activation of a cellular protein is the phosphorylated state of a cellular protein.
19. The method of claim 5 , wherein the interferon-induced activation of a cellular protein is the phosphorylated state of a cellular protein.
20. The method of claim 1 , wherein the RNA virus is a respiratory syncytial virus with a mutation in the NS2 gene.
21. The method of claim 2 , wherein the RNA virus is a respiratory syncytial virus with a mutation in the NS2 gene.
22. The method of claim 3 , wherein the RNA virus is a respiratory syncytial virus with a mutation in the NS2 gene.
23. The method of claim 4 , wherein the virus is an RNA virus.
24. The method of claim 23 , wherein the RNA virus is a respiratory syncytial virus with a mutation in the NS2 gene.
25. The method of claim 1 , wherein the RNA virus is an Ebola virus with a mutation in the VP35 gene.
26. The method of claim 2 , wherein the RNA virus is an Ebola virus with a mutation in the VP35 gene.
27. The method of claim 3 , wherein the RNA virus is an Ebola virus with a mutation in the VP35 gene.
28. The method of claim 23 , wherein the RNA virus is an Ebola virus with a mutation in the VP35 gene.
29. The method of claim 4 , wherein the viral interferon antagonist is respiratory syncytial virus NS2.
30. The method of claim 5 , wherein the viral interferon antagonist is respiratory syncytial virus NS2.
31. The method of claim 4 , wherein the test agent is an antibody or antisense compound.
32. The method of claim 5 , wherein the test agent is an antibody or antisense compound.